Patent · US Active

HIV vaccine formulation

US10934328B2 · kind B2 · utility

0Cited by
16References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 20, 2019
Grant dateMar 2, 2021
Priority date—
Expiry dateMar 20, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16134
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.